I have two questions. I would like both parties to answer the first, and then the final question is for the Canadian Diabetes Association.
First, with respect to the suggestions for improving the transparency and accountability of the CDR, you offer that all interested parties could provide CDR with recommendations of qualified reviewers for its consideration. Can you share with us what kinds of measures should be implemented to ensure that the process is free of conflict of interest prior to the initiation of the review? How do you think reviewers should be chosen?
Question number two is for the CDA. I gather that the CDA disagreed with the recommendations that the CDR made on four specific diabetes drugs. Could you be a bit more specific about why you think the CDR erred in its consideration of these drugs?
What I want to know is whether the objection is based on the concept of CDR-type reviews and reimbursement recommendations, or the manner in which CDR conducts its reviews.